Evolus, Inc. filings document financial results and corporate disclosures for a Nasdaq-listed performance beauty company focused on aesthetic injectables. Its 8-K reports furnish quarterly and preliminary results, disclose capital-structure actions such as the termination of an at-the-market sales agreement, and record financing arrangements including a senior secured asset-based revolving credit facility.
The company’s proxy and current reports also cover governance and compensation matters, including a classified board structure, director reclassification, officer appointments and departures, equity award plans, executive compensation, shareholder meeting proposals, and related-party disclosures tied to its public-company reporting obligations.
Stewart Brady, a director of Evolus, Inc. (EOLS), purchased 30,000 shares of the issuer's common stock on 08/15/2025 at a weighted average price of $6.8162 per share, increasing his beneficial ownership to 88,629 shares. The Form 4 reports the shares were bought in multiple trades at prices ranging from $6.7699 to $6.82, and the filing was signed by Jeffrey J. Plumer as attorney-in-fact on 08/18/2025. The transaction is reported as a purchase and the ownership is listed as direct.
Timothy P. Lynch reported beneficial ownership of 4,094,489 shares of Evolus, Inc. common stock, representing 6.3% of the class based on 64,685,419 shares outstanding as of August 1, 2025. The filing shows Mr. Lynch holds 3,492,130 shares with sole voting and dispositive power and 602,359 shares with shared voting and dispositive power. The Schedule identifies the issuer's principal executive offices at 520 Newport Center Drive, Newport Beach, California.
The filing is a Schedule 13G and includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer. The reporting person’s address is listed as 70 SW Century Dr, STE 100 PMB 1257, Bend, OR 97702, and the signature is dated 08/15/2025.
Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 2,474,843 shares of Evolus, Inc. common stock, representing 3.8% of the outstanding class based on 64,685,419 shares outstanding as stated in the filing. The holdings are reported as shared voting and shared dispositive power; none of the Reporting Persons claim sole voting or sole dispositive power. The filing states the Master Fund directly holds the shares and Perceptive Advisors acts as its investment manager, with Mr. Edelman as managing member.
Caligan Partners LP and its managing partner David Johnson filed a Schedule 13G reporting shared beneficial ownership of 3,341,970 shares of Evolus, Inc. common stock, representing 5.2% of the class based on 64,475,589 shares outstanding as of May 2, 2025. The reporting persons state the shares are held by Caligan Partners Master Fund LP and a managed account and are owned in the ordinary course of business, not to influence control of the company. Caligan is organized in Delaware and Mr. Johnson is a U.S. citizen. Principal business address for the filers is 780 Third Avenue, 30th Floor, New York, NY 10017.